Conatus Pharmaceuticals Inc. (CNAT) stock fell over 50% today amid disappointing results for the company’s 2b ENCORE-PH clinical trial in NASH cirrhosis.
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 17% …
On Monday, Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that the FDA has granted Orphan Drug Designation to the company’s drug candidate IDN-7314, for the treatment …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced it has entered into an exclusive option, collaboration and license agreement for the global development and commercialization of …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that abstracts for four posters — two addressing clinical results and two addressing preclinical results with the company’s …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced positive top-line results from the three-month, open-label second stage of the company’s multicenter Phase 2 clinical trial of emricasan, …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced the delivery of a late breaker oral presentation at The International Liver Congress™ 2016, the Annual Meeting of the …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that a poster addressing results in bothex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the appointment …
Healthcare analysts weigh in today on insulin drug maker MannKind Corporation (NASDAQ:MNKD) and biotechnology company Conatus Pharmaceuticals Inc (NASDAQ:CNAT). While one analyst is quite bearish on MannKind …
